Alnylam Pharmaceuticals, Inc. (ALNY)
404.24
-10.96
(-2.64%)
USD |
NASDAQ |
Dec 10, 16:00
406.00
+1.76
(+0.43%)
After-Hours: 20:00
Alnylam Pharmaceuticals Cash from Investing (Quarterly): 501.11M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc. | -2.43B |
| Glaukos Corp. | -3.993M |
| Bristol Myers Squibb Co. | -1.702B |
| BridgeBio Pharma, Inc. | 4.464M |
| Vertex Pharmaceuticals, Inc. | -117.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 325.11M |
| Cash from Financing (Quarterly) | -448.35M |
| Free Cash Flow | 221.36M |
| Free Cash Flow Per Share (Quarterly) | 2.279 |
| Free Cash Flow to Equity (Quarterly) | 279.39M |
| Free Cash Flow to Firm (Quarterly) | 359.62M |
| Free Cash Flow Yield | 0.42% |